These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

675 related articles for article (PubMed ID: 33983621)

  • 41. Application of the Estimand Framework to Anesthesia Trials.
    De Silva AP; Leslie K; Braat S; Grobler AC
    Anesthesiology; 2024 Jul; 141(1):13-23. PubMed ID: 38743905
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Current Practices in Choosing Estimands and Sensitivity Analyses in Clinical Trials: Results of the ICH E9 Survey.
    Fletcher C; Tsuchiya S; Mehrotra DV
    Ther Innov Regul Sci; 2017 Jan; 51(1):69-76. PubMed ID: 30236003
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Tell me what you want, what you really really want: Estimands in observational pharmacoepidemiologic comparative effectiveness and safety studies.
    Luijken K; van Eekelen R; Gardarsdottir H; Groenwold RHH; van Geloven N
    Pharmacoepidemiol Drug Saf; 2023 Aug; 32(8):863-872. PubMed ID: 36946319
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Seeking harmony: estimands and sensitivity analyses for confirmatory clinical trials.
    Mehrotra DV; Hemmings RJ; Russek-Cohen E;
    Clin Trials; 2016 Aug; 13(4):456-8. PubMed ID: 26908545
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Assessing the ratio of means as a causal estimand in clinical endpoint bioequivalence studies in the presence of intercurrent events.
    Lou Y; Jones MP; Sun W
    Stat Med; 2019 Nov; 38(27):5214-5235. PubMed ID: 31621943
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Estimands for clinical endpoints in Tuberculosis treatment randomized controlled trials: a retrospective application in a completed trial.
    Weir IR; Dufault SM; Phillips PP
    Res Sq; 2023 Nov; ():. PubMed ID: 37986887
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Assessing the Impact of COVID-19 on the Clinical Trial Objective and Analysis of Oncology Clinical Trials-Application of the Estimand Framework.
    Degtyarev E; Rufibach K; Shentu Y; Yung G; Casey M; Englert S; Liu F; Liu Y; Sailer O; Siegel J; Sun S; Tang R; Zhou J;
    Stat Biopharm Res; 2020 Jul; 12(4):427-437. PubMed ID: 34191975
    [No Abstract]   [Full Text] [Related]  

  • 48. Defining estimands for efficacy assessment in single arm phase 1b or phase 2 clinical trials in oncology early development.
    Englert S; Mercier F; Pilling EA; Homer V; Habermehl C; Zimmermann S; Kan-Dobrosky N
    Pharm Stat; 2023; 22(5):921-937. PubMed ID: 37403434
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Estimands for overall survival in clinical trials with treatment switching in oncology.
    Manitz J; Kan-Dobrosky N; Buchner H; Casadebaig ML; Degtyarev E; Dey J; Haddad V; Jie F; Martin E; Mo M; Rufibach K; Shentu Y; Stalbovskaya V; Sammi Tang R; Yung G; Zhou J
    Pharm Stat; 2022 Jan; 21(1):150-162. PubMed ID: 34605168
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Estimands-A Basic Element for Clinical Trials.
    Pohl M; Baumann L; Behnisch R; Kirchner M; Krisam J; Sander A
    Dtsch Arztebl Int; 2021 Dec; 118(51-52):883-888. PubMed ID: 34857075
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Treatment effect quantification for time-to-event endpoints-Estimands, analysis strategies, and beyond.
    Rufibach K
    Pharm Stat; 2019 Mar; 18(2):145-165. PubMed ID: 30478869
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Reflections on estimands for patient-reported outcomes in cancer clinical trials.
    Lawrance R; Skaltsa K; Regnault A; Floden L
    J Biopharm Stat; 2023 Nov; ():1-11. PubMed ID: 37980609
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The attributable estimand: A new approach to account for intercurrent events.
    Darken P; Nyberg J; Ballal S; Wright D
    Pharm Stat; 2020 Sep; 19(5):626-635. PubMed ID: 32198954
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Decentralized Clinical Trials: Scientific Considerations Through the Lens of the Estimand Framework.
    Izem R; Zuber E; Daizadeh N; Bretz F; Sverdlov O; Edrich P; Branson J; Degtyarev E; Sfikas N; Hemmings R
    Ther Innov Regul Sci; 2024 May; 58(3):495-504. PubMed ID: 38315407
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Adherence, per-protocol effects, and the estimands framework.
    Keene O
    Pharm Stat; 2023; 22(6):1141-1144. PubMed ID: 37477077
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Not Available].
    Lynggaard H; Keene ON; Mütze T; Rehal S
    Pharm Stat; 2024 Aug; ():. PubMed ID: 39115134
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Estimands for factorial trials.
    Kahan BC; Morris TP; Goulão B; Carpenter J
    Stat Med; 2022 Sep; 41(22):4299-4310. PubMed ID: 35751568
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Modified reference based imputation and tipping point analysis in the presence of missing data due to COVID-19.
    Jin M; Liu R; Robieson W
    Contemp Clin Trials; 2021 Nov; 110():106575. PubMed ID: 34597836
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Translating questions to estimands in randomized clinical trials with intercurrent events.
    Stensrud MJ; Dukes O
    Stat Med; 2022 Jul; 41(16):3211-3228. PubMed ID: 35578779
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Special issue PRO] A demonstration of estimands and sensitivity analyses for time-to-deterioration of patient reported outcomes.
    Floden L; DeRosa M; Roydhouse J; Beaumont JL; Hudgens S
    J Biopharm Stat; 2024 Apr; ():1-15. PubMed ID: 38686622
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 34.